Cardurion
Burlington, US · 3 known investors
Cardurion develops novel cardiovascular therapeutics targeting unmet needs in heart failure and rare arrhythmias through PDE9 and CaMKII inhibition. The company combines in-house drug discovery with strategic partnerships and clinical expertise to advance groundbreaking treatments for patients with cardiovascular disease.